Breaking: Trump strikes deal on obesity drugs with Lilly, Novo

Medicare and Medicaid secure deep discounts on the costly drugs in a potential public health victory.

Log In    Subscribe BREAKING NEWS   Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices By Daniel Payne and Elaine Chen SERGEI GAPON/AFP via Getty Images The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by Novo Nordisk and Eli Lilly — offering more coverage for Medicare and Medicaid beneficiaries and lowering the prices across the board.   The administration argued that giving millions more people access to these drugs represents a major victory in the fight against chronic disease. The precise timeline for the coverage expansion, and the extent of who will gain access, remain unclear. READ MORE Sign up for D.C. Diagnosis Washington never stops. Cut through the noise with our essential updates on health care politics and policy. Learn more. In Case You Missed It 1   FTC raises concern about Novo Nordisk attempt to acquire obesity startup Metsera By Elaine Chen and Ed Silverman 2   The FDA is a mess, but don't blame it for everything By Adam Feuerstein 3   Not just Rogaine: Biotech investors see promise in a new wave of hair loss treatments By Allison DeAngelis 4   Experts worry FDA's credibility is being shredded by scandal and 'soap opera' By Matthew Herper and Lizzy Lawrence Don't miss out on another STAT investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us